Published in Cost Eff Resour Alloc on October 13, 2016
Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread? Pharmacoeconomics (2017) 0.75
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA (2009) 5.60
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int (2009) 1.31
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int (2011) 1.26
Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics (2011) 1.21
Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin (2004) 1.12
A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Qual Life Res (2014) 1.12
Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res (2012) 0.97
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics (2011) 0.96
Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation. Pharmacoeconomics (2002) 0.88
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract (2012) 0.86
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy (2013) 0.84
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ (2012) 0.82
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int (2013) 0.80
Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice. Pharmacoeconomics (2015) 0.80
Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2011) 0.79
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. Osteoporos Int (2012) 0.78
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme. Aust Health Rev (2017) 0.77